Vectura Group (LON:VEC)‘s stock had its “buy” rating reaffirmed by Morgan Stanley in a research note issued on Friday, May 24th, Digital Look reports. They presently have a GBX 160 ($2.09) price objective on the stock. Morgan Stanley’s price target would indicate a potential upside of 97.53% from the company’s current price.
Other equities analysts also recently issued reports about the company. Numis Securities restated a “buy” rating and issued a GBX 160 ($2.09) target price on shares of Vectura Group in a research note on Wednesday, May 8th. Peel Hunt reaffirmed a “hold” rating and set a GBX 119 ($1.55) price target on shares of Vectura Group in a report on Friday, May 24th. Finally, Shore Capital reaffirmed a “hold” rating on shares of Vectura Group in a report on Friday, May 24th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of GBX 122.86 ($1.61).
LON:VEC opened at GBX 81 ($1.06) on Friday. The stock has a market capitalization of $538.33 million and a P/E ratio of -6.14. Vectura Group has a one year low of GBX 65.85 ($0.86) and a one year high of GBX 90.15 ($1.18). The company has a debt-to-equity ratio of 0.81, a current ratio of 2.35 and a quick ratio of 1.90.
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Further Reading: Cost of Capital
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.